

Development of CK1 α selective molecular glue degrader for p53 wild-type solid cancer



ONCOLOGY	Preclinical
Product Type	Small molecule – Molecular Glue Degradator
Indication	TP53 wild-type solid tumors
Target	CK1 α
MoA(Mechanism of Action)	Cancer cell apoptosis by CK1 α degradation-mediated p53 activation
Competitiveness	<ul style="list-style-type: none">• First-in-class in solid tumor• Highly selective targeted degradation of CK1α
Development Stage	Preclinical
Route of Administration	Oral administration